Kurs & Likviditet
Kalender
2024-10-31 | Kvartalsrapport 2024-Q3 |
2024-08-16 | Kvartalsrapport 2024-Q2 |
2024-06-05 | Ordinarie utdelning NAVA 0.00 NOK |
2024-06-04 | Årsstämma 2024 |
2024-04-30 | Kvartalsrapport 2024-Q1 |
2024-02-15 | Bokslutskommuniké 2023 |
2023-11-01 | Kvartalsrapport 2023-Q3 |
2023-08-11 | Kvartalsrapport 2023-Q2 |
2023-06-02 | Ordinarie utdelning NAVA 0.00 NOK |
2023-06-01 | Årsstämma 2023 |
2023-05-11 | Kvartalsrapport 2023-Q1 |
2023-02-16 | Bokslutskommuniké 2022 |
2022-11-01 | Kvartalsrapport 2022-Q3 |
2022-08-12 | Kvartalsrapport 2022-Q2 |
2022-06-03 | Ordinarie utdelning NAVA 0.00 NOK |
2022-06-02 | Årsstämma 2022 |
2022-05-10 | Kvartalsrapport 2022-Q1 |
2022-02-17 | Bokslutskommuniké 2021 |
2021-11-04 | Kvartalsrapport 2021-Q3 |
2021-08-13 | Kvartalsrapport 2021-Q2 |
2021-06-04 | Ordinarie utdelning NAVA 0.00 NOK |
2021-06-03 | Årsstämma 2021 |
2021-05-11 | Kvartalsrapport 2021-Q1 |
2021-02-18 | Bokslutskommuniké 2020 |
2020-11-06 | Kvartalsrapport 2020-Q3 |
2020-08-20 | Kvartalsrapport 2020-Q2 |
2020-06-04 | Ordinarie utdelning NAVA 0.00 NOK |
2020-06-03 | Årsstämma 2020 |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-03-11 | Extra Bolagsstämma 2020 |
2020-02-13 | Bokslutskommuniké 2019 |
2019-11-01 | Kvartalsrapport 2019-Q3 |
2019-08-23 | Kvartalsrapport 2019-Q2 |
2019-05-29 | Ordinarie utdelning NAVA 0.00 NOK |
2019-05-28 | Årsstämma 2019 |
2019-05-15 | Kvartalsrapport 2019-Q1 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-12-20 | Extra Bolagsstämma 2018 |
2018-11-09 | Kvartalsrapport 2018-Q3 |
2018-08-24 | Kvartalsrapport 2018-Q2 |
2018-06-08 | Ordinarie utdelning NAVA 0.00 NOK |
2018-06-07 | Årsstämma 2018 |
2018-05-30 | Kvartalsrapport 2018-Q1 |
2018-02-15 | Bokslutskommuniké 2017 |
2017-11-10 | Kvartalsrapport 2017-Q3 |
2017-07-28 | Kvartalsrapport 2017-Q2 |
2017-06-07 | Ordinarie utdelning NAVA 0.00 NOK |
2017-06-06 | Årsstämma 2017 |
2017-05-10 | Kvartalsrapport 2017-Q1 |
2017-02-15 | Bokslutskommuniké 2016 |
2017-01-13 | Extra Bolagsstämma 2017 |
2016-11-11 | Kvartalsrapport 2016-Q3 |
2016-08-18 | Kvartalsrapport 2016-Q2 |
2016-06-21 | Ordinarie utdelning NAVA 0.00 NOK |
2016-06-20 | Årsstämma 2016 |
2016-05-11 | Kvartalsrapport 2016-Q1 |
2016-02-18 | Bokslutskommuniké 2015 |
2015-10-30 | Extra Bolagsstämma 2015 |
2015-10-30 | Kvartalsrapport 2015-Q3 |
2015-08-21 | Kvartalsrapport 2015-Q2 |
2015-06-09 | Ordinarie utdelning NAVA 0.00 NOK |
2015-06-08 | Årsstämma 2015 |
2015-04-28 | Kvartalsrapport 2015-Q1 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-10-31 | Kvartalsrapport 2014-Q3 |
2014-08-22 | Kvartalsrapport 2014-Q2 |
2014-06-10 | Årsstämma 2014 |
2014-05-06 | Kvartalsrapport 2014-Q1 |
2014-02-27 | Bokslutskommuniké 2013 |
2013-11-01 | Kvartalsrapport 2013-Q3 |
2013-08-30 | Kvartalsrapport 2013-Q2 |
2013-06-13 | Kapitalmarknadsdag 2013 |
2013-05-23 | Årsstämma 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-02-15 | Bokslutskommuniké 2012 |
2012-02-10 | Bokslutskommuniké 2011 |
2011-10-21 | Kvartalsrapport 2011-Q3 |
2011-08-25 | Kvartalsrapport 2011-Q2 |
2011-05-05 | Kvartalsrapport 2011-Q1 |
2011-04-14 | Årsstämma 2011 |
2011-02-04 | Bokslutskommuniké 2010 |
2010-10-28 | Kvartalsrapport 2010-Q3 |
2010-08-26 | Kvartalsrapport 2010-Q2 |
2010-05-05 | Kvartalsrapport 2010-Q1 |
2010-03-25 | Årsstämma 2010 |
2010-02-11 | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Oslo June 1[th], 2021 - Navamedic ASA ("Navamedic", OSE: NAVA) announces the launch of new products in the Nordics.
Medical Nutrition is a strategically important area for Navamedic and to further strengthen our presence, we have now launched three new products in this category. The first to be launched is Glycosade Lemon for the dietary treatment of Glycogen Storage Disease (GSD), an inborn error of metabolism. The other two, K.Flo and K.Yo, are both used for the dietary management of drug-resistant epilepsy or other conditions for which a ketogenic diet is indicated.
"We are proud to announce that the addition of these new products to the existing portfolio will enhance our strategy of delivering a complete range of products for patients with metabolic disorders or drug-resistant epilepsy. This will give patients who are on a very strict dietary regimens an increased choice of options which will make the adherence to dietary treatment easier." says Fredrik Karlsson, KAM Medical Nutrition of Navamedic.
Navamedic has products that combine the best of cutting-edge research with the lifestyle demands of modern living. By launching new products to meet complex dietary treatments, Navamedic will continue to offer new product lines throughout the year, always with the patient at the core.
The Medical Nutrition business segment is based on the sale of products for the treatment of inborn errors of metabolism (IEM). Within Medical Nutrition, Navamedic is a Nordic distributor of products purchased from the UK based company Vitaflo International ltd, a subsidiary of Nestlé. Navamedic's vendor Vitaflo has more than 30 years of experience in producing specialist nutritional products for Inborn Errors of Metabolism (IEM).
Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA, +46 70 257 99 71 alexander.lidmejer@navamedic.com